Axsome Therapeutics, Inc. (AXSM)

Axsome Therapeutics Inc (AXSM) is a clinical-stage biopharmaceutical company that develops therapies for the treatment of central nervous system (CNS) disorders. The company’s product candidates include AXS-05, which is being evaluated for treatment-resistant depression (TRD), major depressive disorder (MDD), and agitation associated with Alzheimer’s disease (AD); AXS-07, which is being developed for the treatment of migraine; AXS-12, which is being developed for the treatment of narcolepsy; AXS-14, which is being developed for the treatment of fibromyalgia; and AXS-09, which is being developed for the treatment of neurological disorders associated with certain metabolic disorders. Axsome Therapeutics was founded in 2012 and is based in New York, New York.